LC Sentinel was just DR-70.
Nothing more, nothing less. LC Sentinel was not some magical elixir combining DR-70 with anything else. This is evident from the old Radient PR's.
The name "LC Sentinel" might belong to Provista but who cares. Gartner's business GCDx is trying to sell DR-70 / LC Sentinel / "the Lung Cancer Test" / Onko-Sure / whatever name you want to throw on it. These are all names for the exact same thing.
Anyone who wants to manufacture or sell this test can do it now because Radient's patent expired and there is no pending patent application.
Provista's breast cancer test does not use DR-70 or anything else that involves Radient. Apparently, since Provista has not specifically stated this, it is the topic of debate for some reason. When Provista releases an abstract of their Breast Cancer Test study, the abstract will describe the science in no uncertain terms, and this "debate" will end.
As for Gartner being a VP of anything at Provista - that has nothing to do with Radient or RXPC. And Gartner IS USING DR-70 -- he can use DR-70 because it is not protected intellectual property any more.
News 
Market Data 
Discover 
